Search Immortality Topics:

Page 5«..4567..1020..»


Category Archives: Diseases

Cancer is a Stem cell Disease – Video


Cancer is a Stem cell Disease
Cancer is a Stem cell Disease A recent publication by Cristian Tomasetti and Bert Vogelstein contributes important arguments to the discourse on the theory o...

By: Gershom Zajicek M.D,

Continued here:
Cancer is a Stem cell Disease - Video

Posted in Diseases | Comments Off on Cancer is a Stem cell Disease – Video

Bone Marrow Stem Cells – Video


Bone Marrow Stem Cells
http://www.cellmedicine.comFrom:cellmedicineViews:16679 35ratingsTime:06:26More inNews Politics

Excerpt from:
Bone Marrow Stem Cells - Video

Posted in Diseases | Comments Off on Bone Marrow Stem Cells – Video

Cytomedix to Present at Upcoming Stem Cell Conferences

GAITHERSBURG, MD--(Marketwire - Oct 23, 2012) - Cytomedix, Inc. ( OTCQX : CMXI ) (the "Company"), a leading developer of biologically active regenerative therapies, today announced that it will present at the First Annual Houston Stem Cell Summit on October 26th and at the 2012 Stem Cell Meeting on the Mesa Conference, October 29th - 30th.The presentations will be given by Edward L. Field, Chief Operating Officer of Cytomedix.

Houston Stem Cell Summit Houston, TX, Oct 26 - 27

Presentation Time: 9:50 AM, Friday, October 26th, 2012 Location: The Houstonian Hotel, 111 North Post Oak Lane, Houston, TX

The Houston Stem Cell Summit will bring together, for the first time; the many and varied stem cell research and commercialization activities in Texas with the leading global researchers and entrepreneurs. The latest therapeutic research regarding the use of adult stem and progenitor cell therapies will be featured.The Summit will also provide a forum for entrepreneurs to discuss their latest efforts to commercialize stem cell therapies, and to debate and discuss FDA and other legal and regulatory issues impacting stem cell research and commercialization. Participating Texas institutions include: Baylor College of Medicine, Texas Heart Institute, Texas A&M, Rice University, and MD Anderson.The organizers expect more than 35 speakers, 300 attendees, and participation from a dozen of the leading commercial stem cell companies.

2012 Stem Cell Meeting on the Mesa Investor and Partnering Forum La Jolla, CA, Oct 29 - 30

Presentation Time: 1:30 PM, Monday October 29th, 2012 Location: Sanford Consortium, 2880 Torrey Pines Scenic Drive, La Jolla, CA

Edward Field will also be a panelist in a discussion "Getting to Market: Keys to Regulatory Success" on October 30th at 2:00pm. This session will examine the regulatory challenges facing regenerative medicine companies and the strategies they employ to reach the market.

The 2012 Stem Cell Meeting on the Mesa is aimed at bringing together senior members of the business development and scientific research communities in regenerative medicine to advance stem cell science into cures for debilitating diseases and injuries. The meeting features a nationally recognized Scientific Symposium attended by more than 600 leading scientists and researchers alongside the regenerative medicine industry's premier annual Investor and Partnering Forum designed to facilitate a bridge between academia and industry through one-on-one meetings and further the translation of clinical research.

About Cytomedix, Inc. Cytomedix, Inc. is a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell separation products that enhance the body's natural healing processes. The Company's advanced autologous technologies offer clinicians a new treatment paradigm for wound and tissue repair. The Company's patient-derived PRP systems are marketed by Cytomedix in the U.S. and distributed internationally. Our commercial products include the AutoloGel System, cleared by the FDA for wound care and the Angel Whole Blood Separation System. The Company is developing novel regenerative therapies using our proprietary ALDH Bright Cell ("ALDHbr") technology to isolate a unique, biologically active population of a patient's own stem cells. A Phase 2 trial evaluating the use of ALDHbr for the treatment of ischemic stroke is underway. For additional information please visit http://www.cytomedix.com.

Safe Harbor Statement Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's ability to successfully integrate the Aldagen acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2011 and other subsequent filings. These filings are available at http://www.sec.gov.

Read more here:
Cytomedix to Present at Upcoming Stem Cell Conferences

Posted in Diseases | Comments Off on Cytomedix to Present at Upcoming Stem Cell Conferences

Microscopic packets of stem cell factors could be key to preventing lung disease in babies

ScienceDaily (Oct. 31, 2012) Researchers at Boston Children's Hospital have found that microscopic particles containing proteins and nucleic acids called exosomes could potentially protect the fragile lungs of premature babies from serious lung diseases and chronic lung injury caused by inflammation.

The findings explain earlier research suggesting that while transplanting a kind of stem cell called mesenchymal stem cells (MSCs) could help reduce lung injury and prevent inflammation in a mouse model, the fluid in which the cells were grown was more effective than the cells themselves.

The research team -- led by Stella Kourembanas, MD, and S. Alex Mitsialis, PhD, and spearheaded by led by Changjin Lee, PhD, all of the Division of Newborn Medicine at Boston Children's -- published their findings online on October 31 in the journal Circulation.

Premature babies often struggle to get enough oxygen into their underdeveloped lungs, resulting in hypoxia and the need for ventilator assistance to breathe. Their lungs are particularly susceptible to inflammation, which can lead to poor lung growth and chronic lung disease. Inflammation is also often associated with pulmonary hypertension (PH) -- dangerously high blood pressure in the pulmonary artery (the vessel that carries blood from the heart to the lungs), which can have both short- and long-term consequences.

"PH is a complex disease fueled by diverse, intertwined cellular and molecular pathways," according to Kourembanas, who chairs Boston Children's Newborn Medicine division. "We have treatments that improve symptoms but no cure, largely because of this complexity. We need to be able to target more than one pathway at a time."

In 2009, Kourembanas, Mitsialis and others showed that injection of MSCs could prevent PH and chronic lung injury in a newborn mouse model of the disease. The results were puzzling, though, because the team found that few of the injected stem cells actually engrafted within the lungs. They also found that they could achieve better results by injecting just conditioned media -- the fluid the cells had been grown in -- than by injecting the cells themselves.

"We knew, then, that the significant anti-inflammatory and protective effects we saw had to be caused by something released by the MSCs," Kourembanas explained. "The question was, what?"

To answer that question, the research team grew mouse MSCs in the laboratory and searched the conditioned media for any secreted factors. They came upon exosomes, which many cell types, including MSCs, produce and release as a kind of communication vehicle.

The team found that injecting just purified exosomes from MSCs reduced lung inflammation and prevented the occurrence of PH in their animal model of PH. In contrast, neither MSC-conditioned media depleted of exosomes nor exosomes purified from other cell types had any effect on inflammation or PH in the model, indicating that something unique to the MSC-produced exosomes is required for their protective effect.

"We are actively working to figure out what exactly within the MSC-produced exosomes causes these anti-inflammatory and protective effects," Kourembanas said. "But we know that these exosomes contain microRNAs as well as other nucleic acids. They also induce expression of specific microRNAs in the recipient lung."

Excerpt from:
Microscopic packets of stem cell factors could be key to preventing lung disease in babies

Posted in Diseases | Comments Off on Microscopic packets of stem cell factors could be key to preventing lung disease in babies

Nobel Laureates Yamanaka and Gurdon Meet on UCSF Campus for Stem Cell Symposium

Shinya Yamanaka, MD, PhD, left, and John Gurdon, PhD, speak at an Oct. 24 press briefing during the ISSCR-Roddenberry International Symposium on Cellular Reprogramming held at UCSF's Mission Bay campus.

More than two weeks after winning the 2012 Nobel Prize for Physiology or Medicine Shinya Yamanaka, MD, PhD, and John Gurdon, PhD, were able to celebrate their monumental achievement together for stem cell discoveries made half a century and half a world apart.

The pair appropriately met for the International Symposium on Cellular Reprogramming, held in San Francisco last week at UCSFs Mission Bay campus by the International Society for Stem Cell Research (ISSCR) and the Roddenberry Center for Stem Cell Biology and Medicine at the Gladstone Institutes.

During an Oct. 24 press briefing, Yamanaka president of the ISSCR, a Gladstone senior investigator and a UCSF professor of anatomy urged his home country of Japan to invest more in science, while Gurdon, of the Gurdon Institute in Cambridge, England, advocated for allowing well-informed patients to assume risks of clinical trials that might benefit them, without a burdensome amount of regulation.

The work for which they won the Nobel Prize, to be awarded in Stockholm in December, began in 1958 before Yamanaka was born when Gurdon cloned a normal tadpole by putting the DNA-enveloping nucleus of a skin cell from a frog into a de-nucleated frog egg. The experiment showed that the DNA from a fully mature cell body called a somatic cell still contains the genetic information needed to program the orderly development of a complete organism.

This knowledge inspired Yamanaka in his own work decades later.

Shinya Yamanaka, president of the International Society for Stem Cell Research (ISSCR), presented at the ISSCR-Roddenberry International Symposium on Cellular Reprogramming last week.

In 2007, Yamanaka showed that the manipulation of just four genes within a cell can induce a specialized skin cell to become a pluripotent stem cell one capable of spinning off virtually any cell type in the body. This achievement was one few thought possible, and it has inspired thousands of scientists and raised hopes for new therapies to replace damaged organs and tissues.

In the long term, the induced pluripotent stem (iPS) cells first developed by Yamanaka may offer some advantages over embryonic stem cells in the study of disease and in the development of novel tissue transplants for damaged organs. Embryonic stem cells still are regarded as the gold standard of pluripotency, Yamanaka said, but iPS researchers are making rapid progress.

My hope is that one day we can use iPS cells instead of embryonic stem cells, Yamanaka said at the briefing.

Continue reading here:
Nobel Laureates Yamanaka and Gurdon Meet on UCSF Campus for Stem Cell Symposium

Posted in Diseases | Comments Off on Nobel Laureates Yamanaka and Gurdon Meet on UCSF Campus for Stem Cell Symposium

No stem cell act at the moment – Liow

KUALA LUMPUR, Oct 29 (Bernama) -- The health ministry did not have plans to introduce a stem cell act at the moment, said the minister, Datuk Seri Liow Tiong Lai.

He said, the ministry's four guidelines on stem cell research sufficiently served as standards to which practitioners and scientists involved in stem cell research and therapy should adhere to, ensured patients were out of harm's way.

The guidelines would provide a framework for researchers, clinicians and companies involved in research, clinical trials and manufacture of stem cells, he noted.

"There is no stem cell act in this country. But the guidelines alone are sufficient to provide the grounds and ethical environment to carry out their work," Liow told reporters after launching the 1st National Stem Cell Congress here today.

The four guidelines are National Standards For Haemopoietic Stem Cell Therapy, National Standards For Cord Blood Banking and Transplantation, National Standards For Stem Cell Transplantation and Guidelines On Stem Cell Research and Therapy.

Liow said: "Before we came up with the guidelines, we formed a committee to discuss the details of the research. The committee also included Jakim and religious officials for their views."

He said the use of cell-based therapies should be done strictly under clinical trials. Prior to the clinical trials, there must be sufficient evidence to show safety, quality and efficacy.

Meanwhile, Liow said stem cell therapy in Malaysia was developing well in government, as well as university hospitals, noting that the number of patients receiving bone marrow and stem cell transplantation for leukaemia and solid tumours was on the rise.

He said a total of 213 haemopoietic stem cell transplants were performed and registered in the country, the majority of which centred on malignant disorders, namely leukaemia and lymphoma.

Currently, the minister disclosed, there were 11 haemopoietic transplant centres performing haemopoietic stem cell transplants in the country, including Ampang Puteri Specialist Hospital, Haematology Department (Ampang Hospital), Haemopoietic Stem Cell Transplant Unit (Universiti Sains Malaysia Hospital) and Paediatric BMT Unit, Institute of Paediatrics Kuala Lumpur Hospital.

Continued here:
No stem cell act at the moment - Liow

Posted in Diseases | Comments Off on No stem cell act at the moment – Liow